| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5205400
Max Phase: Preclinical
Molecular Formula: C26H21F2N3O3
Molecular Weight: 461.47
Associated Items:
Representations
Canonical SMILES: COc1cc(F)cc(N2c3ccc(F)cc3C(=O)N3CCc4c([nH]c5ccc(OC)cc45)C32)c1
Standard InChI: InChI=1S/C26H21F2N3O3/c1-33-17-4-5-22-20(13-17)19-7-8-30-25(24(19)29-22)31(16-9-15(28)10-18(12-16)34-2)23-6-3-14(27)11-21(23)26(30)32/h3-6,9-13,25,29H,7-8H2,1-2H3
Standard InChI Key: BDXSHNZVIWKIIW-UHFFFAOYSA-N
Associated Targets(Human)
HepG2 (196354 Activities)
Huh-7 (12904 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
SK-HEP1 (1155 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
HCCLM9 (119 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
L02 (4864 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
SMMC-7721 (5516 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 461.47 | Molecular Weight (Monoisotopic): 461.1551 | AlogP: 5.31 | #Rotatable Bonds: 3 |
| Polar Surface Area: 57.80 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
| #RO5 Violations: 1 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: | CX Basic pKa: | CX LogP: 4.84 | CX LogD: 4.84 |
| Aromatic Rings: 4 | Heavy Atoms: 34 | QED Weighted: 0.45 | Np Likeness Score: -0.51 |
References
| 1. Lei F, Xiong Y, Wang Y, Zhang H, Liang Z, Li J, Feng Y, Hao X, Wang Z.. (2022) Design, Synthesis, and Biological Evaluation of Novel Evodiamine Derivatives as Potential Antihepatocellular Carcinoma Agents., 65 (11.0): [PMID:35639640] [10.1021/acs.jmedchem.2c00520] |
Source
Source(1):